Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about Re-Appointment of Independent Directors
BIOFILCHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biofil Chemicals & Pharmaceuticals has announced the re-appointment of two Independent Directors for a second and final five-year term. Mr. Ashok Kumar Ramawat (DIN: 08818263) will serve from 25 August 2025 to 24 August 2030, while Mr. Satish Beohar (DIN: 09220291) will serve from 30 June 2026 to 29 June 2031. The decision was made by the Board on 12 August 2025 based on the recommendation of the Nomination and Remuneration Committee, and is subject to shareholder approval at the upcoming 40th Annual General Meeting. Both directors have significant experience — Ramawat has 45 years in the pharmaceutical industry and Beohar has 35 years in sales and marketing. The company confirmed that neither director is debarred from accessing the capital markets by SEBI or any other authority, and neither is related to any other director on the board.
This is a routine corporate governance disclosure confirming board continuity with experienced independent oversight. It is unlikely to have any material impact on the stock price or shareholder value.